Cor Therapeutics Integrilin
This article was originally published in Pharmaceutical Approvals Monthly
Company expects to submit data to FDA in the first quarter to support a higher dosing regimen of eptifibatide for patients undergoing coronary stent procedures. Cor is also studying combined use of Integrilin and TNKase (tenecteplase) with Schering-Plough and Genentech. The combination is expected to move into Phase III testing by the end of the yea
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.